Moleculin Biotech Valuation
| MBRX Stock | USD 2.62 0.03 1.13% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Moleculin Biotech secures a last-minute Real Value of $3.87 per share. The latest price of the firm is $2.62. Our model forecasts the value of Moleculin Biotech from analyzing the firm fundamentals such as Return On Equity of -1.41, current valuation of (1.06 M), and Shares Owned By Insiders of 3.30 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Moleculin Biotech's valuation include:
Price Book 1.0636 | Enterprise Value -1.1 M | Enterprise Value Ebitda 0.5229 |
Undervalued
Today
Please note that Moleculin Biotech's price fluctuation is risky at this time. Calculation of the real value of Moleculin Biotech is based on 3 months time horizon. Increasing Moleculin Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Moleculin Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Moleculin Stock. However, Moleculin Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.62 | Real 3.87 | Target 8.0 | Hype 2.58 |
The intrinsic value of Moleculin Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Moleculin Biotech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Moleculin Biotech helps investors to forecast how Moleculin stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Moleculin Biotech more accurately as focusing exclusively on Moleculin Biotech's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Moleculin Biotech's intrinsic value based on its ongoing forecasts of Moleculin Biotech's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Moleculin Biotech's closest peers.
Moleculin Biotech Cash |
|
Moleculin Valuation Trend
Analysing the historical paterns of Moleculin Biotech's enterprise value and its market capitalization is a good way to estimate and gauge the value of Moleculin Biotech over time and is usually enough for investors to make rational market timing decisions.
Moleculin Biotech Total Value Analysis
Moleculin Biotech is now projected to have valuation of (1.06 M) with market capitalization of 7.96 M, debt of 574 K, and cash on hands of 58 M. The negative valuation of Moleculin Biotech may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Moleculin Biotech fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(1.06 M) | 7.96 M | 574 K | 58 M |
Moleculin Biotech Asset Utilization
One of the ways to look at asset utilization of Moleculin is to check how much profit was generated for every dollar of assets it reports. Moleculin Biotech secures a negative usage of assets of -0.57 %, losing $0.005745 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Moleculin Biotech shows how discouraging it operates for each dollar spent on its assets.Moleculin Biotech Ownership Allocation
Moleculin Biotech secures 3.3 % of its outstanding shares held by insiders and 15.34 % owned by institutional investors.Moleculin Biotech Profitability Analysis
Net Loss for the year was (29.77 M) with profit before overhead, payroll, taxes, and interest of 0.About Moleculin Biotech Valuation
Our relative valuation model uses a comparative analysis of Moleculin Biotech. We calculate exposure to Moleculin Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Moleculin Biotech's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -127 K | -133.3 K |
Moleculin Biotech Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 2 M |
Moleculin Biotech Current Valuation Indicators
Valuation refers to the process of determining the present value of Moleculin Biotech and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Moleculin we look at many different elements of the entity such as Moleculin's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Moleculin Biotech, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Moleculin Biotech's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Moleculin Biotech's worth.Additional Tools for Moleculin Stock Analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.